Precision Medicine for L/GCMN and Melanoma 1

RecruitingOBSERVATIONAL
Enrollment

6,000

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

March 1, 2026

Study Completion Date

November 30, 2026

Conditions
Melanoma (Skin Cancer)Nevi and Melanomas
Interventions
OTHER

Gradient Boosting Survival Analysis (GBSA),

It is a non-deep learning method that effectively addresses data scarcity issues. GBSA adapts the gradient boosting machine algorithm for survival analysis, particularly accommodating censored data. In survival analysis, patients are represented by a triplet (xi, δi, Ti), where xi is the feature vector, Ti is the time to event, and δi indicates whether the observation is censored. Our goal is to estimate the survival function S(t), representing the probability of a patient surviving beyond time t, and the hazard function λ(t), indicating the instantaneous probability of an event occurring at time t.

OTHER

Concordance index

The survival model performance will be evaluated using the concordance index (c-index), a metric particularly suited for survival analysis. The c-index assesses the predictive accuracy of our model by comparing predicted and observed event times. A high c-index indicates that our model effectively predicts the order of patient hazard given its input features.

Trial Locations (1)

08036

RECRUITING

Hospital Clínic de Barcelona (Dermatology service), Barcelona

All Listed Sponsors
collaborator

Hospital Clinic of Barcelona

OTHER

lead

Fundacion Clinic per a la Recerca Biomédica

OTHER